• IRIDEX Announces 2018 Second Quarter Results and Raises Full Year 2018 Guidance

    Source: Nasdaq GlobeNewswire / 02 Aug 2018 16:05:18   America/New_York

    MOUNTAIN VIEW, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter and six months ended June 30, 2018.

    Second Quarter Highlights

    • Cyclo G6™ product revenue increased approximately 58% year-over-year
    • Shipped 11,500 G6 probes
    • Shipped 125 G6 laser systems
    • Approval of Cyclo G6 laser system in South Korea
    • Total revenue of $10.3 million

    “I’m pleased with the strong Cyclo G6 momentum we saw in the second quarter.  With a growing body of clinical evidence and support from global key opinion leaders, our priority remains to further drive utilization and expand the installed base worldwide,” said William M. Moore, President and CEO. “The safety, efficacy, and versatility that MicroPulse therapy offers patients is creating traction with doctors as the next generation treatment for glaucoma.  We look forward to continuing to execute on this trajectory.”

    Second Quarter 2018 Financial Results
    Revenue for the three months ended June 30, 2018 increased 3% to $10.3 million from $10.0 million during the same period of the prior year. The increase in revenue was primarily due to growth from G6 product revenues, partially offset by a decrease in retina product revenues.

    Gross profit for the second quarter of 2018 was $4.3 million, or 41.4% gross margin, compared to $4.5 million, or 44.9% gross margin, in the same period of the prior year. Gross margin was primarily impacted by unfavorable geographic mix, partially offset by the benefit of higher margin G6 revenues and a decrease in manufacturing overhead spending.

    Operating expenses for the second quarter of 2018 were $7.6 million compared to $7.2 million in the same period of the prior year. This increase is attributable to investments to support the Company’s commercial infrastructure, including increased sales and marketing expenses.

    Loss from operations for the second quarter of 2018 was $3.3 million, compared to loss from operations of $2.7 million for the same period of the prior year.

    Cash and cash equivalents were $16.0 million as of June 30, 2018.

    Guidance for Full Year 2018
    IRIDEX increased its guidance range for G6 probes and G6 systems. The Company now expects G6 probe shipments of 42,000 to 46,000 and G6 system shipments of 370 to 420.  This compares to previous 2018 guidance of G6 probe shipments of 40,000 to 45,000 and G6 system shipments of 350 to 400. The Company also raised the lower end of its 2018 total revenue guidance to a range of $38 million to $41 million. This compares to prior 2018 total revenue guidance of $37 million to $41 million.

    Webcast and Conference Call Information
    IRIDEX’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET.  Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 5656348.  A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.iridex.com.  A telephone replay will also be available beginning Thursday, August 2, 2018 through Friday, August 3, 2018, by dialing (855) 859-2056 for domestic callers or (404) 537-3406 for international callers, using conference ID: 5656348.

    About IRIDEX
    IRIDEX Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.

    Safe Harbor Statement
    This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the future demand and order levels for the Company's products, future operating expenses, the adoption and effect of Company products on its results, the markets in which the Company operates, usage and efficacy of the Company's products, the Company’s guidance for fiscal 2018 and future financial results, and the Company's strategic and operational plans and objectives. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 30, 2017, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

    Investor Relations Contact
    Lynn Pieper Lewis or Leigh Salvo
    (415) 937-5404
    investors@iridex.com

    IRIDEX Corporation
    Condensed Consolidated Statements of Operations
    (In thousands, except per share data)
    (unaudited)

     Three Months Ended  Six Months Ended
      
     June 30,  July 1,  June 30,  July 1,  
     2018  2017  2018  2017  
                      
    Total revenues$10,304  $10,002  $19,813  $20,485  
    Cost of revenues 6,036   5,507   11,623   11,525  
    Gross profit 4,268   4,495   8,190   8,960  
                      
    Operating expenses:               
    Research and development 901   1,369   2,005   2,708  
    Sales and marketing 4,168   3,654   8,218   6,577  
    General and administrative 2,481   2,213   4,866   4,274  
    Total operating expenses 7,550   7,236   15,089   13,559  
    Loss from operations (3,282)  (2,741)  (6,899)  (4,599) 
    Other income (expense), net 6   (1)  24   (3) 
    Loss from operations before provision for income taxes (3,276)  (2,742)  (6,875)  (4,602) 
    Provision for income taxes 4   8   8   14  
    Net loss$(3,280) $(2,750) $(6,883) $(4,616) 
    Net loss per share:                 
    Basic$(0.28) $(0.24) $(0.59) $(0.40) 
    Diluted$(0.28) $(0.24) $(0.59) $(0.40) 
                      
    Weighted average shares used in computing net loss per share               
    Basic 11,644   11,546   11,636   11,532  
    Diluted 11,644   11,546   11,636   11,532  


    IRIDEX Corporation
    Condensed Consolidated Balance Sheets
    (In thousands and unaudited)

      June 30, December 30, 
      2018 2017 
    Assets       
    Current assets:       
    Cash and cash equivalents $16,045 $21,707 
    Accounts receivable, net  7,142  7,863 
    Inventories  9,093  9,381 
    Prepaid expenses and other current assets  653  500 
    Total current assets  32,933  39,451 
    Property and equipment, net  1,396  1,403 
    Intangible assets, net  108  116 
    Goodwill  533  533 
    Other long-term assets  173  143 
    Total assets $35,143 $41,646 
            
            
    Liabilities and Stockholders' Equity       
    Current liabilities:       
    Accounts payable $2,243 $1,724 
    Accrued compensation  2,392  2,459 
    Accrued expenses  2,322  2,153 
    Accrued warranty  762  1,536 
    Deferred revenue  2,316  2,520 
    Total current liabilities  10,035  10,392 
            
    Long-term liabilities:       
    Accrued warranty  164  199 
    Other long-term liabilities  511  533 
    Total liabilities  10,710  11,124 
            
    Stockholders' equity:       
    Common stock  126  126 
    Additional paid-in capital  60,138  59,385 
    Accumulated other comprehensive income  41  - 
    Accumulated deficit  (35,872) (28,989)
    Total stockholders' equity  24,433  30,522 
    Total liabilities and stockholders' equity $35,143 $41,646 


    Primary Logo

Share on,